Business Description
Elicio Therapeutics is a Boston-based company working to develop new cancer treatments that use the body's immune system to fight the disease. Its most advanced therapy, ELI-002, is currently in Phase II clinical trials and is designed to target a specific group of genetic mutations commonly responsible for driving cancer growth. The company is also advancing two additional treatments, ELI-007 and ELI-008, which take a similar approach but target different cancer-causing genetic changes. All three therapies work by directing the immune response through the lymph nodes, where it can be most effectively activated.
